Clinical trials: Heart Failure, Reduced Ejection Fraction
Aortic Stenosis, Aortic Regurgitation
Transcatheter Aortic Valve Replacement With Extracorporeal Life System Support
Transcatheter aortic valve replacement (TAVR) has a high risk and a high mortality rate in the treatment of aortic stenosis/regurgitation patients with cardiac insufficiency.
- Conditions
- Aortic Stenosis, Aortic Regurgitation, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT04160624
- Testing
- transcatheter aortic valve replacement
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xijing Hospital
Acute Heart Failure With Reduced Ejection Fraction
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05139615
- Testing
- APD418
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF
US Benchmarking Clinical Study
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy
- Trial name
- EMS-CT-1 (NCT07215715)
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- eMyosound SAS
Heart Failure
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
The objective of this study is to evaluate whether valsartan/sacubitril leads to a superior improvement in endothelial function and endocrine status compared to valsartan alone.
- Trial name
- VASCEND (NCT03168568)
- Where
- Switzerland
- Volunteers
- 79 people
- Sponsor
- University of Zurich
HFrEF - Heart Failure With Reduced Ejection Fraction
Impact of Barostimulation on Hemodynamics in Adults With Heart Failure
This study evaluates the effects of the implantation and adjustment of the CVRx Barostim device in adult patients with heart failure with reduced ejection fraction who are receiving maximally tolerated doses of guideline directed…
- Trial name
- BREATHE-HF (NCT07335510)
- Testing
- Baroreflex Activation Therapy
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- Columbia University
Heart Failure, Systolic Heart Failure
Effects of Postural Balance Exercises in Patients With Heart Failure
In this study, the effects of core stabilization and computerized wobble board exercise training programs on postural balance and functional exercise capacity in patients over 60 years of age with heart failure will be…
- Conditions
- Heart Failure, Systolic Heart Failure, Diastolic Heart Failure
- Trial name
- NCT04937790
- Testing
- Core stabilization group(CSG), Wobble board group (WBG)
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Giresun University
Heart Failure with Preserved Ejection Fraction
Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is becoming the most common cause of heart failure worldwide, in part, driven by a rising prevalence of obesity.
- Trial name
- NCT06510270
- Testing
- Dapagliflozin 10 mg once daily, Loop diuretics, Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
- Volunteers
- 70 people
- Sponsor
- Aswan University
Heart Failure; With Decompensation
Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
There will be two populations in this study: control group, and intervention group. These groups will undergo propensity matching to account for confounders and minimize selection bias.
- Trial name
- CATAS-HF (NCT04095416)
- Testing
- ACE compression wrap
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Henry Ford Health System
Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
This is a multi-center, randomized, sponsor open-label, participant- and investigator-blinded, placebo-controlled, single and multiple dose study to investigate the safety and tolerability of XXB750 in HFrEF/HFmrEF.
- Trial name
- NCT05328752
- Testing
- XXB750
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Systolic Heart Failure, Cardiac Resynchronization Therapy
ECG for Programming in CRT
Patients with heart failure and left bundle branch block benefit from Cardiac Resynchronization Therapy (CRT) that delivers pacing from right ventricle (RV) and left ventricle (LV) synchronously, resulting in electrical…
- Conditions
- Systolic Heart Failure, Cardiac Resynchronization Therapy, Electrocardiography
- Trial name
- EPIC (NCT03936608)
- Testing
- Programming individualized RV-LV pacing offset to optimize ECG, Nominally programming CRT device without RV-LV offset
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Heart Failure and Reduced Ejection Fraction, Obesity & Overweight
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide.
- Conditions
- Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide
- Trial name
- DUAL-HFrEF (NCT07738276)
- Testing
- Tirzepatide
- Volunteers
- 60 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Heart Failure
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body…
- Trial name
- NCT05658458
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- 12 sites in India
- Volunteers
- 205 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction
Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT
SEMI trial is a single-center, real-world based prospective cohort study. The study enrolled acute heart failure patients admitting to the hospital and intended to accept heart failure therapy.
- Trial name
- SEMI (NCT05799638)
- Testing
- Guideline-Directed Medication Treatment (GDMT)
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Chongqing Medical University
Heart Failure, Coronary Artery Disease
3/7 Resistance Training Method in Cardiac Rehabilitation
Aim of the clinical monocentric study is to assess the resistance training exercise intervention in patients with Heart Failure with reduced Ejection Fraction (HFrEF) and coronary artery disease that will best improve peak oxygen…
- Trial name
- NCT05696990
- Testing
- 3/7 Resistance Training Method, 3X9 Resistance Training Method
- Where
- Belgium
- Volunteers
- 112 people
- Sponsor
- Université Libre de Bruxelles
Heart Failure, Heart Failure Hospitalization
Teach-Back Discharge Education to Improve Self-Care and Reduce 30-Day Readmissions in Heart Failure Patients
This study aimed to improve how patients with heart failure understand and manage their condition after leaving the hospital. Many heart failure patients are readmitted within 30 days due to confusion about their discharge…
- Conditions
- Heart Failure, Heart Failure Hospitalization, Readmission, Hospital
- Trial name
- NCT07280208
- Testing
- Teach-Back Discharge Education
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Nova Southeastern University
Heart Failure
Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure
The primary purpose of this mechanistic study is to evaluate the vasodilatory effects of AZD3427 in adult patients with heart failure and will be performed at approximately 2 study sites in the United Kingdom.
- Trial name
- NCT04890548
- Testing
- AZD3427
- Sponsor
- AstraZeneca
Myocardial Infarction, Heart Failure, Systolic
VItamin D as a Novel Determinant of Injurious Cardiac Remodelling After acuTE Myocardial Infarction
To provide insight into why vitamin D levels at baseline predict an adverse outcome including hospitalisation, we will establish whether baseline vitamin D levels are an independent marker of LV remodelling in patients…
- Trial name
- VINDICATE-MI (NCT03086746)
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- University of Leeds
Heart Failure, Iron Deficiencies
IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure
The aim of this study is to observe the effect of intravenous ferric derisomaltose in participants with non-ischaemic heart failure (LVEF<40%), iron deficiency (TSATS<20%) and established on heart failure therapy including…
- Trial name
- IRONHEART (NCT06542822)
- Testing
- Ferric derisomaltose
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Patient Engagement, Medication Optimization
Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF
The EPIC-HF study will test the effectiveness of a patient empowerment and activation for optimization of Heart Failure with reduced Ejection Fraction (HFrEF) medication plans.
- Conditions
- Patient Engagement, Medication Optimization, Heart Failure With Reduced Ejection Fraction, Patient Activation
- Trial name
- EPIC-HF (NCT03334188)
- Testing
- Patient engagement materials, No Intervention--Usual Care
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- University of Colorado, Denver
Congestive Heart Failure, Left Ventricular Systolic Dysfunction
Sleep-Disordered Breathing in Heart Failure - The SchlaHF-Registry
Objective target of the registry is to investigate the prevalence of SDB as well as the clinical characteristics of patients with and without SDB as well as the predominant type of sdb.
- Trial name
- SchlaHF (NCT01500759)
- Where
- 199 sites in Australia, Germany
- Volunteers
- 6,876 people
- Sponsor
- ResMed